WASHINGTON, DC – The Subcommittee on Oversight and Investigations, chaired by Rep. Tim Murphy (R-PA), has scheduled a hearing for Friday, February 12, 2016, at 9 a.m. in room 2123 of the Rayburn House Office Building. The hearing is entitled, “Outbreaks, Attacks, and Accidents: Combatting Biological Threats.” The subcommittee will hear testimony from members of the Blue Ribbon Study Panel on Biodefense and other experts on:
WASHINGTON, DC – The House Committee on Energy and Commerce today announced its hearing schedule for the week of February 8.
WASHINGTON, DC – Energy and Commerce Committee Chairman Fred Upton (R-MI) and Health Subcommittee Chairman Joseph Pitts (R-PA) today solicited input from members of the health care community on policy changes regarding site-neutral payments, including changes made to certain Medicare hospital reimbursements on a prospective basis (under Section 603 of the Bipartisan Budget Act of 2015).
WASHINGTON, DC – House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Communications and Technology Subcommittee Chairman Greg Walden (R-OR) today wrote to FCC Chairman Tom Wheeler concerned with the commission’s reporting on broadband deployment, video competition, and mobile wireless competition.
WASHINGTON, DC – Bipartisan leaders of the House Energy and Commerce Committee today announced their intention to hold a hearing in March to examine issues related to the ongoing drinking water crisis in Flint, Michigan. Building on the information the committee has been collecting from EPA and the state of Michigan, the committee will seek to gain a comprehensive understanding of the short-and long-term implications of this crisis to the public health and environment.
WASHINGTON, DC – The Subcommittee on Health, chaired by Rep. Joseph Pitts (R-PA), today held a legislative hearing entitled, “Examining Implementation of the Biologics Price Competition and Innovation Act.” The hearing provided an opportunity to get an update on the regulation and approval of biosimilars from the Food and Drug Administration (FDA) as well as an update on the reimbursement policy recently outlined by the Centers for Medicare and Medicaid Services (CMS).